CME/CE

In this episode of KDIGO Conversations in Nephrology, Dr. Carla Nester is joined by Dr. Anne-Marie van de Kar, Professor of Pediatrics at Radboud University Medical Center in the Netherlands, to discuss the role of complement in C3 glomerulopathy (C3G). They begin by defining C3G and exploring its pathophysiology, specifically focusing on the overactivation of the alternative pathway of the complement system.

Then, Drs. Nester and van de Kar delve into the specifics of why the alternative pathway is so central to C3G, including the role of autoantibodies like C3 nephritic factor (C3Nef) and genetic factors. Their discussion also covers the importance of diagnostic testing, including the role of kidney biopsies and biomarker analysis to identify the underlying cause and guide treatment, as well as the limitations of current C5 inhibition therapies and the promise of new treatments that target C3 activation directly.

This episode is supported by Apellis & Sobi.

In this episode of KDIGO Conversations in Nephrology, Dr. Carla Nester, Professor of Internal Medicine and Pediatrics at the University of Iowa's Stead Family Children's Hospital, is joined by Dr. Matthew Pickering, Professor of Rheumatology at Imperial College London.

Together, Drs. Nester and Pickering discuss the role of the complement system in complement-driven versus complement-associated kidney diseases and the clinical implications of this distinction. They explore the pros and cons of targeting different pathways and components of the complement system, such as C3, C5, and C5a. Dr. Pickering shares insights into the importance of understanding the pathophysiology for targeted treatments and how the understanding of complement activation can translate into advancements in complement therapies. The discussion also covers the use of circulating biomarkers to help clinicians potentially better diagnose, prognosticate, and evaluate treatment response.

This episode is a must-listen for anyone interested in the latest developments in nephrology and the future of precision medicine in treating kidney diseases; it’s supported by Apellis and Sobi.

In this episode of KDIGO Conversations in Nephrology, Dr. Carla Nester is joined by Dr. David Kavanagh, Professor of Complement Therapeutics at the National Renal Complement Therapeutic Centre in Newcastle, England, to discuss the diagnosis and management of C3 glomerulopathy (C3G). They cover how patients present and the diagnostic workup required to confirm the diagnosis and rule out other diseases that can mimic C3G. The discussion also focuses on the current and future treatment landscape, including the use of new alternative pathway complement inhibitors and their role in both native kidney disease and post-transplant recurrence.

This episode is supported by Apellis & Sobi.

In this episode of KDIGO Conversations in Nephrology, Dr. Carla Nester is joined by Marianne Silkjaer Nielsen. Not only is Ms. Nielsen the mother of a girl who lives with immune complex-MPGN, but she’s also the founder of CompCure, a not-for-profit association that is dedicated to improving outcomes in patients with C3G and immune complex-MPGN.

Together, their conversation will cover:

• The Diagnostic Journey: Rare diseases often have a long diagnostic journey. A specialized pathologist is often needed to identify the disease, and many patients are not diagnosed until they have severe symptoms.
  
• Therapeutic Challenges: The realization that there is no cure or disease-modifying therapy can be devastating. Furthermore, the lack of widespread experience in these rare diseases among physicians, coupled with a lack of long-term evidence, can lead to suboptimal care and poor outcomes.
  
• Impact of Delayed Treatment: Also discussed is the importance of screening programs for kidney diseases and access to targeted therapies—which until now, were not available—before critical illness sets in.
  
• Future Outlook and Advocacy:

In this episode of KDIGO Conversations in Nephrology, Dr. Carla Nester is joined by Dr. Nicole van de Kar, Professor of Pediatrics at Radboud University Medical Center in the Netherlands, to discuss the role of complement in C3 glomerulopathy (C3G). They begin by defining C3G and exploring its pathophysiology, specifically focusing on the overactivation of the alternative pathway of the complement system.

Then, Drs. Nester and van de Kar delve into the specifics of why the alternative pathway is so central to C3G, including the role of autoantibodies like C3 nephritic factor (C3Nef) and genetic factors. Their discussion also covers the importance of diagnostic testing, including the role of kidney biopsies and biomarker analysis to identify the underlying cause and guide treatment, as well as the limitations of current C5 inhibition therapies and the promise of new treatments that target C3 activation directly.

This episode is supported by Apellis & Sobi.

Wondering how your practice’s use of next-generation retinal agents compares to the experts? Join Dr. Durga Borkar and Dr. Veeral Sheth as they discuss how they are using next-generation agents to free their patients from frequent office visits.

Need to catch up on the latest data surrounding next-generation retinal treatments? Drs. Veeral Sheth and Durga Borkar walk through the most recent efficacy and safety data around faricimab, aflibercept 8 mg, and the PDS with ranibizumab. They also review the latest insights on the use of these treatments in real-world practice.

Join our experts as they examine the integration of perioperative immune checkpoint inhibitors (ICIs) in the management of resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC). Drs. Le Tourneau and Harrington discuss unmet needs and limitations of current treatment and review data from trials supporting the use of perioperative ICIs, emphasizing their event-free survival and pathologic response outcomes. The conversation also addresses multidisciplinary coordination and considerations for managing immune-related adverse events. Variations in treatment guidelines, access, and clinical practice between the US, Europe, and other regions are explored to contextualize the challenges of global implementation and provide strategies for practitioners to improve care.

Neuropsychiatric symptoms (NPS) associated with Alzheimer’s disease (AD), such as psychosis and agitation, affect up to 50% of individuals with AD yet remain underdiagnosed and undertreated in clinical practice. These symptoms accelerate cognitive decline, increase mortality risk, and substantially worsen patient and caregiver quality of life. This broadcast replay will provide a practical and engaging discussion of the underlying pathophysiology of NPS associated with AD, the limitations of off-label antipsychotic use, and emerging therapeutic agents targeting NPS associated with AD.

Learn about emerging data in transthyretin amyloid cardiomyopathy (ATTR-CM) from recent congresses, journal publications, and retrospective database analysis, with practical guidance on integrating these findings into clinical practice to inform treatment strategies and patient management. Findings include reduced atrial fibrillation events and lower rates of cardiovascular hospitalization and all-cause mortality from the Heart Failure Association of the ESC. In addition, a recent publication highlights early and sustained increases in serum transthyretin (TTR) levels that are independently associated with improved survival. Additional insights are drawn from the UK Biobank database, showing that lower TTR levels are linked with a higher burden of chronic comorbidities.